Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Valeant's Bid for Allergan: Winners and Losers

Similar to yesterday, U.S. stocks opened little changed on Tuesday, with the benchmark S&P 500 and the narrower Dow Jones Industrial Average (DJINDICES: ^DJI  ) up 0.42% and 0.41%, respectively, at 10:15 a.m. EDT. Nevertheless, news that activist investor Bill Ackman has teamed up with Valeant Pharmaceuticals (NYSE: VRX  ) on a cash-and-stock offer for Botox maker Allergan (NYSE: AGN.DL  ) ought to spark investors' animal spirits (as well as trepidation in executive suites -- teaming up with a strategic acquirer is a novel variant of the activist investor's approach.) Couple that with reports that Pfizer conducted preliminary discussions with AstraZeneca regarding a $100 billion takeover. The Financial Times reported that the talks, which took place late last year, have since ended, but that didn't stop investors from bidding up AstraZeneca's shares by nearly 9% yesterday.

Valeant said its offer represents a "substantial premium" over Allergan's undisturbed share price of $116.33 on April 10, the day before Ackman's Pershing Square Capital Management crossed the 5% ownership threshold that requires a public disclosure. Pershing Square is now Allergan's largest shareholder, but it's not the only activist investor in the mix: hedge fund ValueAct Capital is Valeant's third-largest shareholder; its president, G. Mason Morfit, sits on the company's board. (Morfit is a busy man, as you may remember he recently joined Microsoft's board.) The market is certainly validating Valeant's interest -- Allergan's shares were trading up nearly 16% to $164.41 at 10:15 a.m. EDT.

When the dust clears, this looks like a terrific offer from the viewpoint of Allergan's shareholders -- no wonder Ackman is supporting the deal. Even before today's pop, Allergan shares were trading at a rich 26 times next 12 months' earnings-per-share estimate.

But Allergan shareholders' good fortune looks like Valeant investors' burden. The economics are more difficult to square for the acquirer, which is why it's curious that ValueAct Capital, a value investor, appears to support the deal. Indeed, another value-oriented investor that owns Valeant shares isn't impressed with the terms of the deal; as Glenn Greenberg, the managing director of Brave Warrior Advisors, told Reuters: "It's almost impossible to turn it into a high return investment if you pay that kind of price." For now, the market disagrees, shares of Valeant are also up 5.1% this morning.

There's still time to boost your 2014 returns with The Motley Fool's top stock
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2923794, ~/Articles/ArticleHandler.aspx, 8/28/2015 3:47:04 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Alex Dumortier

Alex Dumortier covers daily market activity from a contrarian, value-oriented perspective. He has been writing for the Motley Fool since 2006.

Today's Market

updated 6 hours ago Sponsored by:
DOW 16,654.77 369.26 2.27%
S&P 500 1,987.66 47.15 2.43%
NASD 4,812.71 115.17 2.45%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

8/27/2015 4:35 PM
^DJI $16654.77 Up +369.26 +2.27%
AGN.DL $0.00 Down +0.00 +0.00%
Allergan, Inc. CAPS Rating: ****
VRX $234.90 Up +7.66 +3.37%
Valeant Pharmaceut… CAPS Rating: ***